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Cells have evolved a sophisticated proteostasis network to ensure that proteins acquire
and retain their native structure and function. Critical components of this network
include molecular chaperones and protein disaggregases, which function to prevent and
reverse deleterious protein misfolding. Nevertheless, proteostasis networks have limits,
which when exceeded can have fatal consequences as in various neurodegenerative
disorders, including Parkinson’s disease and amyotrophic lateral sclerosis. A promising
strategy is to engineer proteostasis networks to counter challenges presented by specific
diseases or specific proteins. Here, we review efforts to enhance the activity of individual
molecular chaperones or protein disaggregases via engineering and directed evolution.
Remarkably, enhanced global activity or altered substrate specificity of various molecular
chaperones, including GroEL, Hsp70, ClpX, and Spy, can be achieved by minor changes
in primary sequence and often a single missense mutation. Likewise, small changes in
the primary sequence of Hsp104 yield potentiated protein disaggregases that reverse
the aggregation and buffer toxicity of various neurodegenerative disease proteins,
including α-synuclein, TDP-43, and FUS. Collectively, these advances have revealed
key mechanistic and functional insights into chaperone and disaggregase biology. They
also suggest that enhanced chaperones and disaggregases could have important
applications in treating human disease as well as in the purification of valuable proteins
in the pharmaceutical sector.
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INTRODUCTION
The advancement of protein engineering has enriched our understanding of protein structure,
function, and folding. Protein-engineering endeavors have met both challenge and opportunity
in designing proteins with desirable or novel functions. An exciting assortment of approaches
has been developed to optimize starting protein scaffolds, ranging from the development of site-
directed mutagenesis in the early 1980s (Dalbadie-Mcfarland et al., 1982; Sigal et al., 1982; Winter
et al., 1982), to more recent computational design efforts (Jiang et al., 2008; Siegel et al., 2010).
A wide spectrum of proteins have been successfully engineered and evolved to adopt new or
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improved function. From engineering DNA polymerases to
better recognize unnatural nucleotides (Laos et al., 2014),
to introducing catalytic activity into non-enzymatic scaffolds
(Korendovych et al., 2011), protein engineering has enhanced
our repertoire of knowledge far beyond solely a fundamental
understanding of protein structure and function.
Despite such progress, there are major challenges to protein
engineering, mostly rooted in the abundance of constraints
embedded in natural protein sequences and structures (Dutton
and Moser, 2011). Understanding the basis for these constraints
has proven challenging, as evolution has sculpted epistatic
relationships between residues and structural domains in
proteins that are necessary for thermodynamic stability,
dynamics, allostery, or complex assembly (Liberles et al.,
2012; Gong and Bloom, 2014; Perica et al., 2014; Sikosek
and Chan, 2014). Amino acids within natural proteins may
display Müllerian interdependency and consequently may have
accumulated irreversible complexity (Dutton and Moser, 2011).
Moreover, natural proteins may also have been subjected to
multiple, simultaneous and diverse selection pressures leading to
complexity from Darwin’s principle of multiple utility (Dutton
and Moser, 2011). These various historical constraints and
complexities can confound engineering approaches. Indeed,
historical contingency and entrenchment due to epistasis play
a critical role in protein evolution (Weinreich et al., 2006;
Bridgham et al., 2009; Bloom et al., 2010; Gong et al., 2013;
Harms and Thornton, 2014; Shah et al., 2015). For example,
the evolutionary trajectory of influenza nucleoprotein revealed
that stabilizing substitutions were essential in compensating for
otherwise intolerable destabilizing changes that were beneficial
to the protein in an adaptive sense (Gong et al., 2013). Thus,
epistatic relationships between residues pose a large challenge
to protein engineers who seek to achieve more than a modest
improvement in protein activity. Consequently, some groups
have steered away from utilizing natural protein scaffolds as a
starting point for engineering, and instead create completely
artificial, human-made proteins (Lombardi et al., 2000; Faiella
et al., 2009; Anderson et al., 2014; Solomon et al., 2014).
Nonetheless, we are still in the very early phases of designing
artificial proteins for specific functional purposes. Moreover,
the challenges inherent to engineering natural proteins are not
insurmountable and the extent to which epistasis as well as
Müllerian and Darwinian complexity might restrict engineering
is poorly defined. Indeed, surprisingly large and utilitarian gains
in activity can be achieved with remarkably small changes to
natural proteins (Wang et al., 2002; Aponte et al., 2010; Jackrel
et al., 2014; Quan et al., 2014).
It is important to recognize that natural proteins are not
perfect. Moreover, it is not always clear where natural proteins
lie in terms of the adaptive landscape. For example, it is
not known what proportion of natural proteins resides at
local adaptive optima with room for substantial improvement.
Indeed, natural proteins are likely only good enough to get
an organism to reproductive age. Natural selection acts less
powerfully on genetic variation expressed at post-reproductive
age, and thus many proteins likely harbor “late-expressing”
harmful mutations (Medawar, 1952). Some of these mutations
may predispose specific proteins to deleterious misfolding in the
aging individual, as occurs in various fatal neurodegenerative
diseases such as Alzheimer’s disease (AD), Parkinson’s disease
(PD), Huntington’s disease (HD), frontotemporal dementia
(FTD), and amyotrophic lateral sclerosis (ALS), in which protein
misfolding causes selective neuronal degeneration (Cushman
et al., 2010). Moreover, natural molecular chaperones or
proteostasis networks (Balch et al., 2008) in general may be
poorly equipped to counter deleterious protein misfolding in
the context of aging individuals due to a lack of selection
for buffering protein misfolding under these circumstances,
which occur long after reproductive age. Emerging evidence
suggests that the proteostasis network declines in the soma
at reproductive age due to conflict between the germ line
and soma (Labbadia and Morimoto, 2014, 2015a,b). Defining
effective strategies to remediate the toxic protein misfolding
underlying several age-related neurodegenerative diseases is
of great importance. Thus, we are particularly interested in
harnessing the power of protein engineering against detrimental
protein misfolding events. Specifically, we would like to
engineer molecular chaperones or protein disaggregases with
potentiated activity, which might be particularly useful in
the specific environment of declining proteostasis in aging
individuals.
In the context of the extremely crowded cellular environment,
the folding of polypeptide chains into precise functional
structures is a daunting task (van Den Berg et al., 1999; Uversky
et al., 2002; Sarkar et al., 2013). Upon stress, the proteostasis
network may become compromised, and proteins may evade
the various safeguards against improper protein folding and
ultimately aggregate. Molecular chaperones are key players in the
maintenance of proper protein folding and overall proteostasis.
Chaperones are required by newly synthesized proteins to
ensure both accurate folding and to prevent aggregation. Indeed,
chaperones function both cotranslationally and in times of
cellular stress (Hartl and Hayer-Hartl, 2002). Chaperones are also
involved in triaging misfolded proteins for degradation and the
trafficking of proteins (Hartl et al., 2011). Although molecular
chaperones are diverse in terms of structure andmechanism, they
generally identify unstructured or hydrophobic stretches on their
respective client substrates that are inappropriately exposed in
misfolded conformations (Bukau et al., 2000; Hartl and Hayer-
Hartl, 2002). However, variations on this theme abound. For
example, the eukaryotic chaperonin, TRiC, recognizes polar and
nonpolar residues in substrates via a combinatorial mechanism
(Joachimiak et al., 2014). Most chaperones foster effective
folding in an ATP-dependent fashion, where substrate affinity
is regulated by the binding and release of ATP (Hartl and
Hayer-Hartl, 2002). Despite sharing this ATP-driven refolding
activity, different classes of molecular chaperones possess distinct
refolding mechanisms, whereby some release unfolded substrates
to be refolded, and others form a protective cage around the
substrate, allowing for refolding (Hartl and Hayer-Hartl, 2002).
Molecular chaperones as a collective are essential for all life as
spontaneous protein folding in itself is not sufficient (Hartl, 2011;
Horwich, 2011; Rothman and Schekman, 2011). For example,
one type of molecular chaperone, Hsp70, is essential for all
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eubacteria and eukaryotes, but is baﬄingly absent from the
majority of archaebacteria (Large et al., 2009; Powers and Balch,
2013). Hsp60 appears to be essential for almost all life and so far
has been found in every eukaryotic and prokaryotic organism
with the curious exception of Mycoplasma species (Henderson
et al., 2013; Powers and Balch, 2013). These pathogenic eubacteria
have very small genomes and presumably have been able to
dispense with Hsp60 via increased reliance upon Hsp70 or via
evolution of Hsp60 clients to fold propitiously without Hsp60
(Fujiwara et al., 2010; Powers and Balch, 2013; Georgescauld
et al., 2014; Ishimoto et al., 2014). Typically, as genomes and
proteomes expand during evolution so does the number of
representatives from the canonical Hsp90, Hsp70, Hsp60, Hsp40,
and small heat shock protein families (Powers and Balch, 2013).
Undoubtedly, molecular chaperones are influential modulators
of proteostasis, and are indispensable for efficacious folding of
proteins into their native structures in vivo.
One solution to combat detrimental protein misfolding and
aggregation might be to create a completely artificial molecular
chaperone or protein disaggregase de novo. This grand challenge
has not yet been met, but warrants investigation. We are
interested in tailoring existing chaperones and disaggregases to
better refold client substrates. Evolved molecular chaperones
with highly enhanced refolding or aggregation prevention
ability could prove advantageous in targeting misfolded proteins
relevant to neurodegenerative disease. Here, we review several
important examples of chaperone engineering, which highlight
essential themes in successfully developing enhanced chaperone
variants.
AN UNBIASED APPROACH TO
ENGINEERING GroEL
In the early 2000s, Weissman and colleagues successfully
engineered enhanced variants of the Hsp60molecular chaperone,
GroEL (Wang et al., 2002). GroEL is a member of the group
I chaperonins which are found in bacteria, chloroplasts, and
mitochondria (Henderson et al., 2013; Gupta et al., 2014).
Group I chaperonins are comprised of heptameric rings, and
interact with co-chaperone partners to capture substrate in a
protective folding cage (Henderson et al., 2013; Gupta et al.,
2014). GroEL is found in a large number of bacteria, and together
with its co-chaperone GroES is extremely well characterized
(Castanié-Cornet et al., 2014). It is estimated that ∼10% of
cytosolic proteins in E. coli interact with GroEL, as it provides
an environment to hinder aggregation of its substrates, and
favor their folding (Clare and Saibil, 2013). Structurally, GroEL
is composed of two back-to-back heptameric rings, in which
each subunit of the heptamer is comprised of three types
of domains (Clare and Saibil, 2013). Intermediate domains
connect the central apical domain, responsible for binding GroES
and substrates, to the two equatorial domains, which bind
ATP and facilitate interactions between and within subunits
(Figures 1A,B; Saibil et al., 2013). A hydrophobic area in the
apical domain binds substrate polypeptides ranging in size
from∼20 to 60 kDa, which can then be confined to the protective
folding chamber that is sealed by a GroES lid (Castanié-Cornet
et al., 2014; Hayer-Hartl et al., 2016). GroEL can also promote
folding of proteins too large to be encapsulated in the chamber
(Chaudhuri et al., 2009; Hayer-Hartl et al., 2016). The exact
mechanism by which GroEL provides folding assistance to
substrates is still debated and range from GroEL providing a
passive box for aggregation prevention, to actively changing
substrate folding trajectory, to folding through forced unfolding
(Figure 1C; Hendrick and Hartl, 1995; Shtilerman et al., 1999;
Thirumalai and Lorimer, 2001; Horst et al., 2007; Apetri and
Horwich, 2008; Lin et al., 2008; Priya et al., 2013; Saibil et al.,
2013; Yang et al., 2013; Fei et al., 2014; Gupta et al., 2014).
Regardless, the allosteric communication between the two GroEL
rings effectively promotes polypeptide folding, ATP hydrolysis,
and subsequent release of the polypeptide (Jewett and Shea,
2010).
Since GroEL is a thoroughly studied allosteric machine, it is
a well-suited target for chaperone engineering. Using a directed
evolution approach, Weissman and colleagues isolated variants
of GroEL and co-chaperone GroES that showed enhanced ability
to fold green fluorescent protein (GFP; Wang et al., 2002). GFP
was an advantageous substrate for this study in that folding
can be readily followed by monitoring GFP fluorescence in cells
(Wang et al., 2002). Directed evolution comprised of rounds of in
vivo screening coupled with in vitro DNA shuﬄing was used to
attain GroEL/S variants with up to∼8-fold improvement in GFP
folding activity (Figures 1A,B,D). The initial round of evolution
consisted of site-directed mutagenesis in the substrate-binding
region of the chaperonin, as well as random mutagenesis in the
GroEL/S operon (Wang et al., 2002). The library generated from
this round was transformed into GFP-expressing E. coli cells, and
the brightest-glowing colonies were selected for a second round
of evolution comprised of DNA shuﬄing (Wang et al., 2002).
The last cycle of evolution yielded several enhanced variants
with modifications to both components of the GroEL/S machine
(Wang et al., 2002). Importantly, it was determined that the
improvement in folding ability was not reliant on othermolecular
chaperones in the cell, and was solely a function of the changes to
the GroEL/S machine (Wang et al., 2002).
In evolving proteins to generate improved variants, it is
critical to determine whether the observed enhancement is
the result of a broad improvement in activity or increased
specificity toward the substrate used in directed evolution. This
distinction offers insight into the specialization of chaperones
for particular substrates, or their inherent generality toward
a wide breadth of substrates. To this end, Weissman and
colleagues tested the ability of their improved variants to fold
natural GroEL/S substrates. The variants were not effective
at folding the substrates tested, with the exception of one
variant (GroE3−1, see Figure 1A) which could successfully fold
mitochondrial rhodanese (Wang et al., 2002). Interestingly, these
results indicated that the gain in GFP folding activity was derived
from a change in substrate specificity from endogenous substrates
to unnatural GFP, and demonstrated that the enhancement of
GFP folding activity manifested as a trade-off that reduced the
ability of GroEL/S to fold its natural substrates (Wang et al.,
2002).
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FIGURE 1 | GroEL/S protein folding cycle and features of evolved variants. (A) Mutations in evolved GroEL/S variants surface in the first intermediate domain
(int.) and second equatorial domain of GroEL, and throughout GroES (Wang et al., 2002). Interestingly, no mutations arise in the apical substrate-binding region (Wang
et al., 2002). Superscripts in the table (based on Table 1 in Wang et al., 2002) correspond to the GroEL/S variants isolated in the final round of evolution (e.g., A163V,
D490G, and Y71H are found in the GroE3−1 variant). (B) Structure (PBD ID: 1AON) of a GroEL/S subunit in the cis-ring of a GroEL/S-ADP complex (Xu et al., 1997)
showing the positions of mutations (gray spheres) in evolved GroEL/S variants. Colors correspond to (A). Based on Figure 5B in Wang et al. (2002). (C) GroEL/S
protein folding cycle. Substrate binds to GroEL, and upon binding of ATP and GroES to the same ring, substrate is moved into the chamber. The substrate is folded in
the protective cage environment (the exact mechanism is still debated), and is released upon ATP hydrolysis and dissociation of GroES (Hendrick and Hartl, 1995;
Hartl et al., 2011). Only one heptameric GroEL ring is shown for simplicity. (D) Features of evolved GroEL/S variants. Variants isolated from the final round of directed
evolution show enhanced GFP-folding ability, decreased ability to fold natural GroEL/S substrates, and heightened ATPase activity (Wang et al., 2002).
Utilizing a directed evolution approach makes it possible to
uncover interesting chaperone variants in an unbiased fashion,
which is a major strength in terms of fully exploring sequence
space and discovering activity-enhancing mutations that may be
less intuitive. Remarkably, by the final cycle of directed evolution,
mutations in the most improved GroEL/S variants were not
found in the substrate-binding domain of the chaperonin
(despite this region being used for random mutagenesis), but
rather in the N-terminal intermediate domain or near the
nucleotide-binding region (Wang et al., 2002). Consistent with
this finding is work by Kawe and Plückthun, whereby an alternate
strategy to modify the substrate-binding region in the apical
domain of GroEL was employed (Kawe and Plükthun, 2006). To
alter substrate specificity, a library of GroEL variants was created
through randomization of residues throughout the apical domain
that were thought to directly interact with clients (Kawe and
Plükthun, 2006). The library was screened in vivo where tuned
GroEL variants were selected, then more thoroughly scrutinized
in vitro (Kawe and Plükthun, 2006). Interestingly, no variants
with dramatically improved refolding activity were isolated
from engineering solely the substrate-binding region (Kawe and
Plükthun, 2006). The results from this approach highlight the
difficulties of directly targeting the substrate-binding domain for
enhancement of chaperone activity (Kawe and Plükthun, 2006).
Kawe and Plückthun suggest a “narrow mutational window” in
the apical domain, since in addition to binding substrate it must
also bindGroES, which is critical in the allosteric regulation of the
GroEL system (Kawe and Plükthun, 2006). Indeed, these findings
illustrate the difficulty of engineering natural proteins due to
constraints imposed by Darwin’s principle of multiple utility.
Mutations that enhanced GroEL activity increased the ATPase
activity of GroEL, and improved the ability of GroES to
inhibit GroEL ATPase activity (Figures 1A,B; Wang et al.,
2002). Additionally, studying a GroES variant that surfaced
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from the screening showed that increasing the overall polarity
of the GroEL/S folding chamber is important for improved
GFP folding activity (Wang et al., 2002). Thus, a delicate
balance between altering the surface properties of the GroEL/S
chamber and the GroEL ATPase cycle was crucial for optimized
activity.
When the GFP folding activity of the GroE3−1 variant
was tested in vitro, the improvement was surprisingly modest
compared to the wild-type chaperonin (Wang et al., 2002). This
result supports the idea that the improved GroEL/S variants are
not necessarily “hyperactivated,” and are actually enhanced in
vivo because they are able to “ignore” other substrates and more
effectively focus on GFP. Thus, this unbiased approach yielded
GFP-specific GroEL/S variants with a contracted substrate
repertoire as opposed to a generally enhanced chaperonin (Wang
et al., 2002), indicating that the generalist GroEL/S can be
tuned to recognize only specific substrates. Engineering the
GroEL/S chaperonin highlights a fascinating theme in chaperone
engineering: very slight modifications (here, only two missense
mutations to GroEL, and one to GroES, were required for
optimized activity) to chaperone sequence can translate to highly
improved folding machines for specific substrates. GroEL/S
has likely evolved to be a generalist to assist the folding of
diverse polypeptides and also functions as a capacitor to buffer
genetic variation and enable evolvability of client proteins (Fares
et al., 2002; Tokuriki and Tawfik, 2009). However, this generalist
activity inescapably incurs a cost of reduced activity against
a specific subset of clients. Thus, GroEL and other molecular
chaperones likely exhibit an unavoidable functional trade off for
some substrates akin to the proverbial jack-of-all-trades, master
of none. This intrinsic and likely historical constraint suggests
that chaperone activity can often be evolved toward specific,
dedicated substrates if necessary, which could have important
implications for specifically targeting proteins that misfold in
neurodegenerative disease.
Interestingly, in eukaryotes the group II chaperonin (group
II chaperonins contain a “built-in” lid and do not require a
GroES-type cochaperone for activity), TRiC, evolved to become
hetero-oligomeric as opposed to homo-oligomeric GroEL (Lopez
et al., 2015). Thus, TRiC contains eight different subunits
per ring (Lopez et al., 2015). Each subunit has a substrate-
binding site, which specifies recognition of distinct substrate
motifs encompassing both polar and nonpolar determinants
(Joachimiak et al., 2014). This subunit diversification enables a
combinatorial mode of substrate binding capable of recognizing
a large and complex sequence space, which might even have
empowered the expansion of eukaryotic proteomes to acquire
essential proteins with novel folds, complex topologies, and
functions (Yam et al., 2008; Joachimiak et al., 2014). Indeed,
many essential eukaryotic proteins, e.g., actin and Cdc20, can
only be folded in a TRiC-dependent manner. Moreover, TRiC
is a powerful inhibitor of misfolding of mutant huntingtin
exon 1 containing an expanded polyglutamine tract, which is
connected with HD (Kitamura et al., 2006; Tam et al., 2009;
Shahmoradian et al., 2013; Sontag et al., 2013). Here too, we
wonder if TRiC activity is limited by functional trade-offs as with
GroEL andGFP (Wang et al., 2002). Clearly, TRiC ultimately fails
to prevent misfolding of polyglutamine-expanded huntingtin in
HD. Thus, perhaps TRiC could be engineered or evolved to
possess enhanced activity against huntingtin or other proteins
connected with neurodegeneration. One interesting strategy
is to harness and perhaps even tailor the substrate-binding
apical domain of TRiC subunit CCT1, ApiCCT1, which can
suffice to antagonize polyglutamine-expanded huntingtin exon 1
misfolding (Sontag et al., 2013). Despite the difficulty in finding
mutations in the apical domain of GroEL that enhance activity
(Wang et al., 2002; Kawe and Plükthun, 2006), whether the same
is true for TriC remains unclear. TriC operates without a GroES
analog (Lopez et al., 2015), and so the constraint of maintaining
GroES binding is alleviated in the context of TriC engineering.
ApiCCT1 demonstrates a remarkable ability to enter cells due
to some sequence similarity with the HIV Tat protein cell-
transduction domain (Sontag et al., 2013). ApiCCT1 delivered
exogenously in this way can exert therapeutic effects in HD cell
models (Sontag et al., 2013).
FLEXIBILITY ENHANCES ACTIVITY IN Spy,
AN ATP-INDEPENDENT CHAPERONE
Many molecular chaperones, such as GroEL, require ATP to
function in protein folding. An interesting deviation from this
ATP dependence is the chaperone Spy, which contains two
LTxxQ motifs and forms a cradle-shaped dimer (Figures 2A,B;
Kwon et al., 2010; Quan et al., 2011). Spy was isolated in E. coli
by Bardwell and colleagues in 2011 (Quan et al., 2011), and its
ATP independence is similar to specific molecular chaperones in
mammals located in the ATP-scarce extracellular space (Wyatt
et al., 2013). In search of E. coli variants that promote protein
stability and folding in the periplasm, Bardwell and colleagues
unearthed a chaperone that stands in its own class in terms of
both structure and function. The basis for the genetic system used
to identify Spy is interesting in that it couples protein folding and
stability to selectable markers, ultimately yielding quantitative
information regarding in vivo protein stability (Quan et al.,
2011). The system is comprised of a fusion between β-lactamase,
necessary for resistance to penicillin V, and DsbA, involved in
resistance to cadmium (Quan et al., 2011). A highly unstable
form of immunity protein 7 (Im7) was inserted between these
two selection markers, allowing for the inherent stability of
Im7 to be paired with the penicillin and cadmium resistance
of the E. coli strain (Quan et al., 2011). E. coli isolates that
demonstrated an increase in penicillin resistance were then
screened for improved cadmium resistance (Quan et al., 2011).
More generally, an enhancement in protein stability translated to
increased resistance to the selection markers, providing powerful
selection criteria to discover new chaperones in the periplasm,
which is devoid of ATP (Quan et al., 2011). In E. coli isolates
that improved the folding of, and thereby increased expression
of Im7, Spy was incredibly overexpressed, constituting almost
half of the protein content of the periplasm (Quan et al., 2011).
Bardwell and colleagues then demonstrated that an increase in
Spy levels is sufficient to enhance Im7 levels, and that Spy served
as a proficient chaperone in terms of helping to refold soluble,
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FIGURE 2 | Functions of Spy in protein folding and features of super-Spy variants. (A) Most mutations in super-Spy variants result in a change in residue
character to hydrophobic (Quan et al., 2014). Of the initial 65 isolated Spy variants, 74% contained the Q100L mutation (Quan et al., 2014). Residues are numbered
according to the mature protein region of Spy. Gray regions denote residues not pictured in (B) structure (this includes the Q25 position). (B) Structure (PDB ID: 3O39)
of a Spy dimer (Quan et al., 2011) showing the positions of mutations (gray spheres) in super-Spy variants. One Spy subunit is shown in dark green, and the other in
light green. Mutations are shown for only one subunit, and LTxxQ motifs (Kwon et al., 2010) are shown for both subunits. Twenty-eight N-terminal residues and 14
C-terminal residues are not pictured as they are disordered (Quan et al., 2011). Colors correspond to (A). (C) Functions of Spy in protein folding. Spy aids in refolding
of substrates independently of ATP. Substrate can fully fold while bound to Spy, or Spy can prevent aggregation by holding substrate in a protective, cradle-shaped
environment (Quan et al., 2011, 2014; Stull et al., 2016). (D) Features of super-Spy variants. Super-Spy variants show tighter binding to the Im7 substrate, increased
structural instability and flexibility, general enhancement of chaperone activity, and an increased hydrophobic patch area (Quan et al., 2014).
misfolded proteins and halting protein aggregation in an in vitro
setting (Quan et al., 2011). The mechanism of Spy-mediated
client folding was recently investigated to determine whether
substrate could fold while bound to Spy, or if it must be released
for folding to ensue (Stull et al., 2016). Interestingly, Spy is
capable of binding with similar affinities the native, intermediate
and unfolded states of its substrate Im7 (Stull et al., 2016). As
such, Im7 can fully fold while bound to Spy, and Spy does not
need to release Im7 for folding to occur (Figure 2C; Stull et al.,
2016). This outcome is fascinating in the greater context of ATP-
independent chaperones, as it suggests a more dynamic role for
these chaperones in substrate folding beyond mere “holdases”
that prevent aggregation.
To engineer enhanced Spy variants, a “stability biosensor” was
employed, comprised of the original unstable Im7 variant that
Spy was shown to stabilize (Quan et al., 2011) directly inserted
into β-lactamase (Quan et al., 2014). Error-prone PCR was used
to create a large plasmid library of Spy variants (Quan et al.,
2014). The library was transformed into an E. coli strain that
lacked Spy, yet contained the biosensor (Quan et al., 2014). Spy
expression was induced by IPTG. Thus, increased IPTG levels
would translate to greater Spy levels and enhanced resistance to
penicillin, with the underlying premise that activity-improving
mutations in Spy would lead to greater penicillin resistance
(Quan et al., 2014). Sixty-five Spy variants that displayed
enhanced penicillin resistance were isolated (Quan et al., 2014).
Interestingly, about three-quarters of the Spy variants surfacing
from the selection possessed a Q100L mutation, while the others
contained a variety of mutations (Figures 2A,B; Quan et al.,
2014). It was established that the enhancement in antibiotic
resistance was not a result of a more general mechanism
such as increased Spy expression, as all of the Spy variants
were present at levels similar to that of wild-type Spy (Quan
et al., 2014). E. coli strains expressing enhanced Spy variants
demonstrated higher minimal inhibitory concentrations than the
strain expressing wild-type Spy, signifying that the isolated Spy
variants possessed greater activity than the wild-type protein
(Quan et al., 2014). Although one might expect the Spy variants
to be deficient in folding other substrates besides Im7 (since
this protein was used in the genetic selection), the variants
surprisingly showed a general enhancement in chaperone activity
toward other substrates (Figure 2D; Quan et al., 2014). Thus,
the Spy variants are distinct from the GroEL variants isolated
by Weissman and colleagues (Wang et al., 2002), which traded
general GroEL function for improved GFP folding activity. The
general chaperone activity of purified Spy variants was tested in
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vitro against chemically denatured aldolase, as well as reduced
denatured α-lactalbumin (Quan et al., 2014). The variants were
termed “super-Spy” as they displayed enhanced aggregation
prevention of these chaperone substrates, and were more active
in aldolase refolding (Figure 2D; Quan et al., 2014).
Spy is a structurally unique chaperone in that it forms a
dimer with a novel cradle-shape, with one very concave surface,
and one very convex surface (Figure 2B; Kwon et al., 2010).
The concave portion of Spy contains hydrophobic patches
believed to be important for substrate binding (Kwon et al.,
2010; Quan et al., 2011). Spy is an incredibly thin protein,
with an average cross-section thickness of the cradle of 9.2 Å
(Quan et al., 2011). Mapping of the individual mutations to
the crystal structure of Spy revealed that most of the super-Spy
mutations clustered together, with the majority residing next to
the two major hydrophobic patches (Figures 2B,C; Quan et al.,
2014). Three mutations including the most common, Q100L,
resulted in a change in residue character from charged or polar
to hydrophobic, which ultimately expanded the hydrophobic
surface area (Figure 2D; Quan et al., 2014). Did these mutations
enhance Spy chaperone activity via increased affinity for
substrate proteins, or through an allosteric mechanism? Bardwell
and colleagues probed the binding of Im7 to Spy through
hydrogen-deuterium exchange, a limited proteolysis approach,
and crosslinking experiments (Quan et al., 2014). Hydrogen-
deuterium exchange studies and limited proteolysis indicated
that large areas of Spy engage Im7 (Quan et al., 2014).
Moreover, the concave surface of Spy served as the major
Im7 binding site (Quan et al., 2014). Super-Spy variants
displayed tighter binding to substrates (Figure 2D; Quan et al.,
2014). Interestingly, a negative correlation between super-Spy
variant activity in vivo and thermodynamic stability in vitro
was found, indicating the less stable Spy variants displayed
improved chaperone activity (Quan et al., 2014). Super-Spy
variants also exhibited a high level of disorder when no substrate
is bound (Quan et al., 2014). Thus, increased Spy flexibility
due to reduced stability enhanced chaperone function and was
accompanied by tighter substrate binding (Figure 2D; Quan
et al., 2014). These findings are another interesting example
of destabilizing mutations proving beneficial, as observed by
Gong et al. in the evolution of influenza nucleoprotein, whereby
stabilizing mutations compensated for otherwise destabilizing
mutations that were actually advantageous (Gong et al., 2013).
It would be intriguing to determine whether mutations can
be isolated that increase the stability of super-Spy variants
without affecting their enhanced chaperone activity. Super-
Spy variants maintained broad chaperone function against
diverse substrates and were not more selective for the substrate
used for selection (Figure 2D; Quan et al., 2014). Remarkably,
Spy homologs in other species possess some of the exact
substitutions that yield super-Spy in E. coli (Quan et al., 2014).
Thus, protein engineering can enhance our understanding of
chaperone function at the amino acid level. This work also raises
a valuable design principle in chaperone engineering: introducing





Hsp104 is a hexameric AAA+ ATPase and protein disaggregase
found in Saccharomyces cerevisiae (DeSantis and Shorter, 2012;
Sweeny and Shorter, 2015). Structurally, six Hsp104 protomers
form a ring-shaped hexamer with a central channel through
which substrate is partially or completely threaded (Parsell et al.,
1994; Lum et al., 2004, 2008; Haslberger et al., 2008; Tessarz et al.,
2008; Castellano et al., 2015; Sweeny and Shorter, 2015; Sweeny
et al., 2015). Each individual Hsp104 protomer is comprised of
an N-terminal domain, two nucleotide-binding domains (NBDs)
that bind and hydrolyze ATP, a coiled-coil middle domain (MD)
that enables communication between domains, and a C-terminal
domain necessary for hexamer formation (Figures 3A,B; Sweeny
and Shorter, 2015).
Hsp104 possesses an unusual ability to rapidly resolubilize
toxic prefibrillar oligomers and amyloid (Shorter and Lindquist,
2004, 2006; Lo Bianco et al., 2008; Shorter, 2008; Vashist et al.,
2010; DeSantis et al., 2012; Klaips et al., 2014; Sweeny and
Shorter, 2015). Hsp104 couples ATP hydrolysis to the refolding
and reactivation of aggregated proteins, and does so optimally
in combination with chaperones Hsp110, Hsp70 and Hsp40
(Figure 3C; Glover and Lindquist, 1998; Shorter and Lindquist,
2008; Shorter, 2011; Rampelt et al., 2012). Hsp104 plays a critical
role in the construction and deconstruction of various yeast
prions (Sweeny and Shorter, 2015; Sweeny et al., 2015), which can
confer selective advantages (Shorter and Lindquist, 2005; Newby
and Lindquist, 2013). Interestingly, Hsp104 is highly conserved
in eubacteria, fungi, protozoa, algae, and plants, yet is absent from
metazoa (Vashist et al., 2010; Erives and Fassler, 2015).
Hsp104 represents an interesting potential therapeutic
modality for human neurodegenerative diseases rooted in
protein misfolding. Hsp104 eradicates preformed fibrils formed
by an array of neurodegenerative disease substrates in vitro,
including tau, polyglutamine, Aβ42, α-synuclein, and PrP (Lo
Bianco et al., 2008; Liu et al., 2011; DeSantis et al., 2012). Despite
this intrinsic ability, substantial levels of Hsp104 are necessary to
achieve only modest disaggregase activity (DeSantis et al., 2012).
With such room for improvement, Hsp104 is poised as an ideal
disaggregase to re-engineer for targeting the toxic misfolded
species underlying multiple neurodegenerative diseases (Jackrel
and Shorter, 2014b, 2015). As the structural details of Hsp104
are not yet well understood, it is not an ideal protein for a
rational design approach. However, an unbiased approach has
been pursued. Thus, a library of Hsp104 MD variants has been
screened in an effort to isolate Hsp104 variants that suppress
toxicity of aggregated α-synuclein (which is connected to PD),
FUS, and TDP-43 (which are connected to ALS and FTD) in
yeast (Jackrel and Shorter, 2014a; Jackrel et al., 2014, 2015). The
MD of Hsp104 was selected for error-prone PCR mutagenesis
as it is a regulatory domain imperative for inter-domain
communication between NBD1 and NBD2, and collaboration
with Hsp70 (Cashikar et al., 2002; Schirmer et al., 2004; DeSantis
and Shorter, 2012; Lee et al., 2013; DeSantis et al., 2014; Sweeny
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FIGURE 3 | Hsp104 disaggregation mechanism and features of potentiated variants. (A) Mutations in potentiated Hsp104 variants surface throughout the
middle domain (MD) in helices 1, 2, 3, and 4 and the small domain of nucleotide-binding domain 1 (SD NBD1) (Jackrel et al., 2014, 2015). Interestingly, substitution of
A503 with any residue except proline (A503X) yielded a potentiated Hsp104 variant. Several other positions (V426, D504, Y507, and N539) can be substituted for
various residues and achieve potentiating effects. Based on Figure 1C in Jackrel et al. (2015). (B) Homology model of an Hsp104 monomer (inset: Hsp104 MD)
showing the positions of mutations (gray spheres) in potentiated Hsp104 variants. Colors correspond to (A). NTD is from PDB ID: 1KHY and NBD1, MD, and NBD2
are from PDB ID: 1QVR (Lee et al., 2003; Li and Sha, 2003). (C) Hsp104 disaggregation mechanism. In collaboration with Hsp70 and Hsp40, Hsp104 unfolds and
threads substrate through the central channel of the hexamer using energy from ATP hydrolysis (DeSantis and Shorter, 2012). (D) Features of potentiated Hsp104
variants. Potentiated Hsp104 variants disaggregate disordered aggregates in the absence of Hsp70 and Hsp40, and possess an enhanced ability to suppress toxicity,
disaggregate, and reverse mislocalization of neurodegenerative disease substrates.
and Shorter, 2015). Limiting library generation to the MD was
advantageous in terms of achieving more profound coverage.
Coupling this library to a powerful screen against α-synuclein,
FUS, and TDP-43 in1hsp104 yeast ultimately led to the isolation
of numerous variants that showed impressive rescue of disease
substrate toxicity (Figures 3A,B,D; Jackrel and Shorter, 2014a;
Jackrel et al., 2014, 2015).
Although the screen yielded an assortment of potentiated
variants at particular residues in the MD (and also the small
domain of NBD1), the A503 position in helix 3 of the MD
surfaced as exceptionally interesting (Jackrel et al., 2014).
Substitution of A503 with any residue except proline yielded
Hsp104 variants that rescue α-synuclein, FUS, and TDP-43
toxicity in yeast (Figures 3A,B; Jackrel et al., 2014). For example,
Hsp104A503V was highly potentiated in its ability to eliminate
protein aggregates, suppress toxicity of disease substrates, and
correct protein mislocalization in yeast (Gokhale et al., 2005;
Jackrel et al., 2014; Torrente et al., 2016). Remarkably, ATPase
activity at either NBD1 or NBD2 was sufficient for this
potentiated activity (Torrente et al., 2016). However, inhibition
of ATPase activity at both NBDs or mutation of key substrate-
binding, pore loop tyrosines to alanine in either NBD abolished
activity (Torrente et al., 2016). It was determined that the
remarkable gain of function in Hsp104A503V was not derived
from lower expression of the disease substrates, nor increased
expression of Hsp104A503V, and was not dependent on the
unfolded protein response, heat shock response, or autophagy
(Jackrel et al., 2014). Curiously, however, Hsp104A503V confers
a growth defect in yeast at 37◦C (Schirmer et al., 2004; Jackrel
et al., 2014). By contrast, Hsp104A503S was less toxic to yeast
at 37◦C and protected dopaminergic neurons from α-synuclein-
induced neurodegeneration in a transgenic C. elegans model
of PD (Jackrel et al., 2014). Furthermore, potentiated Hsp104
variants rescued aggregation and toxicity of a wide range of
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disease-associated FUS, TDP-43 and α-synuclein mutants in
yeast (Jackrel and Shorter, 2014a). These enhanced Hsp104
variants also rescued aggregation and toxicity of TAF15, an
RNA-binding protein (RBP) with a prion-like domain (PrLD)
that is linked to ALS and FTD (Couthouis et al., 2011;
King et al., 2012; Li et al., 2013; Jackrel and Shorter, 2014a).
Interestingly, potentiated Hsp104 variants were unable to rescue
the aggregation or toxicity of EWSR1, another RBP with a
PrLD involved in ALS and FTD, which suggests some degree of
substrate selectivity (Couthouis et al., 2012; Jackrel and Shorter,
2014a).
The finding that almost any residue substitution at the A503
position resulted in an enhanced Hsp104 variant is intriguing,
and suggests that loss of amino acid identity at select positions
in the MD rather than specific mutation underpins potentiation
(Jackrel et al., 2014; Jackrel and Shorter, 2015). Whether the same
is true at other positions in the MD is uncertain, but certainly
several positions (e.g., V426, Y507) can be changed to multiple
amino acids to yield potentiated variants (Figure 3A; Jackrel
and Shorter, 2014b, 2015; Jackrel et al., 2014, 2015). Deletion of
motif 2, helix 3, or helix 4 of the MD also yielded potentiated
Hsp104 variants, whereas deletion of the entire MD or NTD
precluded Hsp104 potentiation (Jackrel et al., 2015; Sweeny et al.,
2015).
To investigate the mechanism underlying Hsp104
potentiation, several biochemical aspects of the most
effective variants were surveyed. Surprisingly, unlike Hsp104,
Hsp104A503V disaggregates disordered aggregates in the absence
of Hsp70 and Hsp40 (Jackrel et al., 2014, 2015; Torrente
et al., 2016). Additionally, Hsp104A503V translocates unfolded
substrates more rapidly than Hsp104, and demonstrates
enhanced unfoldase, remodeling, and disaggregase activity
against a variety of substrates, including α-synuclein, FUS, TDP-
43, TAF15, and SEVI fibrils (Figure 3D; Jackrel and Shorter,
2014a; Jackrel et al., 2014; Castellano et al., 2015). Subunits within
the Hsp104A503V hexamer also appear to collaborate differently
than Hsp104 to promote disaggregation (Jackrel et al., 2014;
Torrente et al., 2014, 2016; Jackrel and Shorter, 2015). A nearly
universal theme that surfaced in the isolated potentiated Hsp104
variants is an elevation of basal ATPase activity to ∼2–4-fold
higher than Hsp104 (Jackrel et al., 2014). Interestingly, several
of the evolved GroEL variants also exhibited elevated ATPase
activity (Wang et al., 2002), indicating that accelerated ATPase
activity may be a common mechanism to enhance chaperone
or disaggregase activity. However, one potentiated variant,
Hsp104D504C, did not display greater ATPase activity than
Hsp104 (Jackrel et al., 2014). Thus, enhanced ATPase activity is
not an absolute requirement for Hsp104 potentiation. Rather, the
one characteristic that unifies the potentiated Hsp104 variants
is the ability to disaggregate disordered aggregates and amyloid
in the absence of Hsp70 and Hsp40 (Figure 3D; Jackrel and
Shorter, 2014a; Jackrel et al., 2014, 2015; Torrente et al., 2016).
This property could be critical as Hsp70 and Hsp40 can become
sequestered or inhibited by disease-associated aggregates and
toxic soluble oligomers (Auluck et al., 2002; Hinault et al., 2010;
Yu et al., 2014).
By harnessing the power of yeast proteinopathy models in
the context of screening a domain-specific library, Hsp104 was
re-engineered to potently eliminate aggregation and toxicity of a
range of misfolded neurodegenerative disease substrates (Jackrel
and Shorter, 2014b, 2015). The potentiated Hsp104 variants
bring to light an interesting motif in chaperone engineering, i.e.,
modifications to regulatory domains as opposed to key residues
in ATPase domains or substrate-binding domains often lead
to notable improvements in activity. In the case of Hsp104,
a single mutation in the regulatory MD yielded dramatically
enhanced activity and a therapeutic gain of function (Jackrel
and Shorter, 2014b, 2015; Jackrel et al., 2015). We hypothesize
that potentiating mutations in the MD relieve its autoinhibitory
function or imitate an allosteric event, e.g., Hsp70 binding to
the MD (Lee et al., 2013), which activates Hsp104 (Jackrel et al.,
2014; Torrente et al., 2016). Additionally, several Hsp104 variants
with substitutions at the A503 position appear less stable in
vitro, and are typically expressed at lower levels in vivo (Jackrel
and Shorter, 2014a; Jackrel et al., 2014, 2015). In this regard,
potentiated Hsp104 variants resemble the super-Spy variants
(Quan et al., 2014) in that increased protein instability correlates
with enhanced function.
Although our potentiated Hsp104 variants suppress the
toxicity of various misfolded disease substrates (Jackrel and
Shorter, 2014b, 2015), this enhanced activity would be best honed
against a specific disease substrate. Fine-tuning hyperactive
Hsp104 variants to improve substrate specificity would be ideal
to avoid the nonspecific unfolding of proteins or other off-target
effects. These nonspecific effects likely underpin the toxicity of
potentiated Hsp104 variants to yeast at 37◦C (Jackrel and Shorter,
2014a; Jackrel et al., 2014). Indeed, work by Sauer and colleagues
provides insight into how to alter the substrate specificity of
a different AAA+ ATPase, ClpX (Farrell et al., 2007). ClpX
unfolds and translocates substrates into the chambered protease
ClpP, and targets client proteins for degradation through the
identification and binding of specific peptide tags (Farrell et al.,
2007). ClpX contains a conserved RKH sequence found in pore
loops that engages specific degradation tags on clients (Farrell
et al., 2007). Single mutations in this RKH sequence greatly alter
the substrate specificity of ClpX (Farrell et al., 2007). Specifically,
changing RKH to AKH decreased degradation of substrates
harboring an ssrA tag, yet improved the degradation of substrates
containing three other types of peptide degradation tags (Farrell
et al., 2007). This change to the pore loop sequence resulted
in a ∼300-fold alteration in substrate specificity, demonstrating
the critical role of the RKH pore loops in terms of ClpXP
substrate recognition (Farrell et al., 2007). A similar tuning
of the conserved substrate-binding pore loops (Sweeny and
Shorter, 2015) in our potentiated Hsp104 variants for particular
clients could prove useful in targeting precise disease substrates,
and ultimately provide deeper insight into the underlying
mechanisms by which this disaggregase recognizes substrates.
DIRECTED EVOLUTION OF ENHANCED
DnaK VARIANTS
Hsp70 family members comprise a diverse group of chaperones
that have widespread functions in protein folding. Hsp70
assumes a critical role in helping to refold aggregated or
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misfolded protein as well as in the folding of newly synthesized
proteins, among other functions (Mayer and Bukau, 2005;
Torrente and Shorter, 2013; Clerico et al., 2015). As such, Hsp70
is a crucial component in protein quality control systems, and
specialized forms interact with a large continuum of substrates
(Mayer and Bukau, 2005; Clerico et al., 2015). Hsp70 client
proteins usually contain hydrophobic stretches, and Hsp70
works cooperatively with its obligate co-chaperone and J-domain
containing, Hsp40 (Hartl and Hayer-Hartl, 2002; Genevaux et al.,
2007), as well as various nucleotide exchange factors (NEFs)
(Rampelt et al., 2011).
Structurally, Hsp70 is comprised of two major domains:
an N-terminal nucleotide-binding domain (NBD) and a C-
terminal substrate-binding domain (SBD) (Figures 4A,B; Kityk
et al., 2012; Clerico et al., 2015). The NBD contains four α-
β subdomains (IA, IB, IIA, and IIB) split into two sections by
an ATP binding site essential for the ATPase activity needed to
power Hsp70 as well as regulating affinity for substrates (Kityk
et al., 2012; Qi et al., 2013). Client proteins bind to a pocket in
the SBD in the β-sheet subdomain (β-SBD) (Kityk et al., 2012).
The SBD also encompasses an α-helical subdomain, termed the
lid domain (LD), which acts analogously to a lid that opens and
closes to allow for substrate binding and release (Figures 4A,B;
Mayer and Bukau, 2005; Kityk et al., 2012). In the absence of
any nucleotide or in the presence of ADP, the two domains share
little contact and do not act as a functional unit, but when ATP
is bound, there is strong allosteric coupling between the two (Qi
et al., 2013). Importantly, when ATP binds Hsp70, the affinity for
substrate in the SBD is substantially reduced (Landry et al., 1992;
Qi et al., 2013). Nonetheless, Hsp70 initially engages substrates
in an ATP-bound “open” state and typically recognizes short
peptide segments (∼7 residues) that are inappropriately exposed
in unfolded proteins (Figure 4C; Landry et al., 1992; Misselwitz
et al., 1998; Mayer and Bukau, 2005; Clerico et al., 2015). The
N-terminal J domain of Hsp40 and substrate binding stimulate
ATP hydrolysis by Hsp70, which induces a conformation change
in Hsp70 such that substrate peptides are now tightly clamped
in an extended form through a groove in the Hsp70 SBD
(Figure 4C; Landry et al., 1992; Misselwitz et al., 1998; Qi
et al., 2013; Clerico et al., 2015). Hsp70 NEFs then promote
exchange of ADP for ATP causing Hsp70 to switch back to a
lower affinity state and substrate is released (Figure 4C; Mayer
and Bukau, 2005). This complex allosteric control over Hsp70
is vital to the overall activity of the chaperone. Indeed, the
effective affinity of Hsp70 for substrates is significantly higher
when Hsp70 runs through this cycle (De Los Rios and Barducci,
2014). Intriguingly, the large conformational changes of Hsp70
during its ATPase cycle are not invariably coupled to changes in
the overall conformation of the bound substrate protein (Sekhar
et al., 2015). Thus, unfolded substrates are likely protected from
aggregation while bound to Hsp70 and can explore secondary
structural propensities inherent to the polypeptide chain (Sekhar
et al., 2015). Hsp70 might also bias folding trajectories of
bound substrates as a secondary amide peptide bond cis-trans
isomerase (Schiene-Fischer et al., 2002; Swain and Gierasch,
2002). Conversely, Hsp70 also possesses a potent unfoldase
activity, which might unfold misfolded structures and reset the
energy landscape thereby providing another opportunity for the
client to fold correctly (Sharma et al., 2010; Clerico et al., 2015).
Of particular relevance to chaperone engineering is the E. coli
Hsp70 homolog, DnaK, which associates with ∼5–18% of newly
synthesized proteins (Bukau et al., 2000). Although both random
mutagenesis and rational design methods (O’brien et al., 1996;
Montgomery et al., 1999; Hu et al., 2002; Fernández Sáiz et al.,
2006) have been employed to explore a range of biochemical
properties of DnaK, a more general evolution of this chaperone
was not undertaken until quite recently. Reinstein and colleagues
utilized a directed evolution approach to isolate DnaK variants
that outperformed wild-type DnaK in the refolding of soluble,
denatured luciferase (Aponte et al., 2010). A clever in vivo
selection process and subsequent in vitro screen uncovered
variants with improved initial refolding rates (Aponte et al.,
2010). A selection scheme was used based on bacterial resistance
to chloramphenicol (Cm) that was dependent on DnaK function.
Bacteria can achieve resistance to Cm bymodifying the antibiotic
with chloramphenicol acetyl transferase (CAT). Aponte et al.
employed a C-terminally truncated CAT variant (CAT_Cd9),
which has reduced ability to fold properly and weakens bacterial
resistance to Cm (Aponte et al., 2010). Overexpression of DnaK
and DnaJ resulted in a rescue of this phenotype, thus allowing
cells to grow in Cm (Aponte et al., 2010). This in vivo selection
system was then exploited to screen dnaK libraries for improved
rescue of CAT_Cd9 folding under Cm selective pressure (Aponte
et al., 2010). In this way, ten enhanced DnaK variants were
isolated from the in vivo selection and subsequent in vitro screen,
and two additional enhanced DnaK variants were found in a
variation of this procedure (Figures 4A,B; Aponte et al., 2010).
Interestingly, none of the enhanced DnaK variants had
mutations in the SBD (Aponte et al., 2010). Instead, half of the
substitutions were located in the LD, and the other half in the
NBD (Figures 4A,B; Aponte et al., 2010). Mutations in the NBD
resided in several different lobes as well as the nucleotide-binding
region, while those in the LD resided on every helix with the
exception of helix B (Aponte et al., 2010). One variant stood
out from the others with single mutations in that it harbors
a C-terminal truncation of 35 amino acids (Cd35), thereby
eliminating the flexible C-terminal tail of DnaK (Figures 4A,B;
Aponte et al., 2010). To gauge the overall chaperone function
of the isolated DnaK variants, each variant was purified and
screened for the ability to aid in refolding chemically denatured
luciferase in vitro (Aponte et al., 2010). Relative to wild-type
DnaK, four variants displayed greater ability to refold luciferase
(in collaboration with co-chaperones) as measured by greater
maximal luminescence values, with three of these variants
exhibiting increased initial refolding rates (Aponte et al., 2010).
Each of the enhanced DnaK variants contained substitutions in
the LD, and interestingly, the Cd35 variant displayed the greatest
increase in chaperone function (Figures 4A,B; Aponte et al.,
2010).
The enhanced activity of Cd35 is surprising as subsequent
studies indicate that the C-terminal region of DnaK improves
in vivo chaperone function, and enhances the in vitro protein
refolding ability of DnaK (Smock et al., 2011). It was proposed
that the C-terminal region interacts with substrate proteins
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FIGURE 4 | Hsp70 (DnaK) protein folding cycle and features of evolved variants. (A) Mutations in evolved DnaK variants localize to the nucleotide binding
domain (NBD) and lid domain (LD) of DnaK, rather than the substrate binding domain (SBD; Aponte et al., 2010). Interestingly, one enhanced variant harbors a
C-terminal truncation of 35 amino acids (Cd35; Aponte et al., 2010). (*) Denotes evolved lid domain DnaK variants emphasized in Aponte et al. (2010) study. ()
Denotes G384A mutation isolated in subsequent evolution of Cd35 DnaK variant (Schweizer et al., 2011). Based on Figure 2 in Aponte et al. (2010). (B) Structure
(PDB ID: 2KHO) of ADP-bound DnaK with a 33 residue C-terminal truncation (Bertelsen et al., 2009) showing the positions of mutations (gray spheres) in evolved
DnaK variants. Colors correspond to (A). Based on Figure 2 in Aponte et al. (2010). (C) DnaK protein folding cycle. Hsp40 (DnaJ) binds and presents substrate to
DnaK. DnaK then weakly interacts with substrate in proximity to DnaJ, and DnaJ stimulates ATPase activity of DnaK thus stabilizing substrate binding. A nucleotide
exchange factor (NEF) promotes nucleotide exchange, Hsp70 returns to the ATP-bound state and substrate is released (Goloubinoff and De Los Rios, 2007; Kim
et al., 2013). (D) Features of evolved DnaK variants. Evolved DnaK variants show increased ability to refold denatured luciferase, and contain mutations in the lid
domain, which plays a role in allosteric regulation of DnaK (Jiang et al., 2005; Vogel et al., 2006; Swain et al., 2007; Aponte et al., 2010).
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in a transient fashion, as it contains a disordered region that
may act as a “flexible tether” between a conserved area of
the tail and the SBD (Smock et al., 2011). The differences
observed in DnaK function when the C-terminal region is
deleted could possibly stem from His-tagged vs. untagged
DnaK being used in these studies (Aponte et al., 2010; Smock
et al., 2011). The Cd35 variant was further investigated in
a subsequent study in which Reinstein and colleagues used
a directed evolution approach to further improve chaperone
function of the truncated mutant (Schweizer et al., 2011). Error-
prone PCR of the Cd35 variant, followed by selection through
the aforementioned CAT_Cd9 selection scheme (Aponte et al.,
2010), resulted in a variant with a G384A amino acid substitution
located in a “hinge position” that connects the NBD and SBD of
DnaK (Figures 4A,B; Schweizer et al., 2011). The G384A/Cd35
double mutant displayed enhanced in vitro refolding-assistance
of denatured firefly luciferase, yet was not as effective as the Cd35
variant alone in this measure of chaperone activity (Schweizer
et al., 2011). Further biochemical analysis revealed that the
G384A/Cd35 double mutant is similar to the single G384A
variant, which is slow to release substrate peptides upon ATP
binding (Schweizer et al., 2011). The G384A/Cd35 doublemutant
is also similar to the Cd35 mutant as it demonstrates faster
peptide binding when ADP is bound. However, these changes
do not appear to act synergistically in improving luciferase-
refolding activity (Schweizer et al., 2011). This result suggests
the G384A/Cd35 double mutant is perhaps more selective in
folding the CAT_Cd9 substrate, as the combination of mutations
offers no enhancement in re-folding the model substrate firefly
luciferase. It is interesting that the G384A/Cd35 double mutant
appears to have altered substrate specificity, and would be
intriguing to test this mutant against a gamut of other substrates
or use this mutant as a starting scaffold for evolution of more
substrate-specific DnaK variants.
Unlike potentiated Hsp104 variants (Jackrel et al., 2014),
the activated DnaK variants exhibited no significant change
in intrinsic ATPase activity compared to wild-type DnaK
(Aponte et al., 2010). Moreover, co-chaperone (DnaJ and GrpE)
stimulation of ATPase activity in the presence and absence of
denatured luciferase was very similar to that of wild-type DnaK,
although the Cd35 variant as well as E585Q displayed lesser GrpE
stimulation overall, possibly indicating differences in nucleotide
exchange involving this NEF (Aponte et al., 2010). Perhaps
the most intriguing result from this selection and screening
approach was that no substitutions in the SBD of DnaK were
obtained (Figures 4A,B). In fact, the improved DnaK variants
harbored mutations in the LD, which plays a role in the allosteric
regulation of DnaK activity (Figures 4A,B,D; Jiang et al., 2005;
Vogel et al., 2006; Swain et al., 2007; Aponte et al., 2010).
Reinstein and colleagues suggest that a change in the tuning
of the DnaK ATPase cycle is critical for enhanced activity
against specific substrates (Aponte et al., 2010). The directed
evolution of DnaK highlights the complexity of predicting
activating mutations in chaperone engineering. Enhancing
substitutions often may surface in domains that are not
directly involved in substrate binding, yet exert crucial allosteric
effects.
Transmission of allosteric signals in Hsp70 involves crucial
interdomain interactions between specific regions of the NBD
and SBD (Zhuravleva et al., 2012; Zhuravleva and Gierasch,
2015). NMR spectroscopy revealed that two interfaces are
stabilized in different states of Hsp70: in the ATP-bound state,
an interaction between the NBD and β-SBD is crucial, whereas
when substrate and ADP are present, a stabilizing interaction
occurs between the β-SBD and α-helical lid (Zhuravleva et al.,
2012; Zhuravleva and Gierasch, 2015). Interestingly, each of these
interactions works to stabilize an allosterically active form of
Hsp70 (in which both substrate and ATP are bound), and the two
forms are engaged in an active “tug-of-war” due to contrasting
energetic contributions (Zhuravleva et al., 2012; Zhuravleva
and Gierasch, 2015). These two interfaces represent “tunable”
landscapes in Hsp70 function, as even slight modification to
these interactions exerts major effects on the balance between
each Hsp70 conformation (Zhuravleva et al., 2012; Zhuravleva
and Gierasch, 2015). As such, a resultant change in chaperone
function through a shift in ATPase activity or substrate affinity
can likely be realized (Zhuravleva et al., 2012; Zhuravleva and
Gierasch, 2015). Intriguingly, one of the lid domain DnaK
variants (K514N) with enhanced chaperone activity that was
isolated in the selection by Reinstein and colleagues, resided at
the β-SBD:α-helical lid interface (Aponte et al., 2010). These
separate findings appear to connect the structural basis for
allosteric communication in DnaK to a functionally relevant in
vivo selection of improved chaperone variants. The bridging of
key structural findings and Hsp70 functional studies will likely
reveal aspects important in effectively engineering augmented
forms of this chaperone.
SELECTIVELY INCREASING Hsp70
AFFINITY FOR NEURODEGENERATIVE
DISEASE SUBSTRATES VIA RATIONAL
DESIGN
Though unbiased screens have proven valuable in uncovering
enhanced chaperone variants, rational design strategies are
another useful avenue for improving specific chaperone features.
Such an approach was employed by Vendruscolo and colleagues
to increase the affinity of Hsp70 for several proteins associated
with neurodegenerative disease (Aprile et al., 2015). To engineer
human Hsp70 to more potently bind and have improved anti-
aggregation activity against α-synuclein and Aβ42, Vendruscolo
and colleagues used a tactic similar to that pioneered to craft
gammabodies for inhibition of fibril assembly (Ladiwala et al.,
2012; Perchiacca et al., 2012). A complementary peptide that
will specifically bind a target epitope in α-synuclein (the NAC
region) or Aβ42 was transplanted onto the C-terminus of Hsp70
(Aprile et al., 2015). The affinity of the grafted Hsp70 variant
designed for α-synuclein, termed GHsp70-NAC, for a model
substrate was similar to that of wild-type Hsp70, indicating
that affinity for other chaperone substrates was unchanged
(Aprile et al., 2015). Similarly, GHsp70-NAC refolded chemically
denatured luciferase similarly to wild-type Hsp70 (Aprile et al.,
2015). Binding experiments using dansyl-α-synuclein showed
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GHsp70-NAC had increased binding affinity for substrate, and
fluorescence competition assays further supported that GHsp70-
NAC favorably bound the target region of α-synuclein (Aprile
et al., 2015). Furthermore, it was demonstrated that GHsp70-
NAC had stronger binding affinity for dansyl-α-synuclein
(relative to wild-type Hsp70) in E. coli cellular extracts (Aprile
et al., 2015).
To rule out the possibility that solely lengthening the C-
terminal region was causing the changes in target substrate
binding, Vendruscolo and colleagues created an Hsp70 to
selectively bind Aβ42 (GHsp70-Aβ) (Aprile et al., 2015). This
Hsp70 variant showed increased binding affinity for Aβ42,
and an affinity for α-synuclein comparable to that of wild-
type Hsp70 (Aprile et al., 2015). Thus, the inclusion of a
complementary peptide, and not just the extension of the C-
terminal region of Hsp70, results in the enhanced binding
of target substrate (Aprile et al., 2015). α-synuclein and
Aβ42 aggregation assays revealed that the grafted Hsp70
variants had enhanced aggregation inhibition activity toward
their target substrates (Aprile et al., 2015). Overall, grafting
a complementary peptide onto Hsp70 designed to bind a
particular substrate is an exciting approach that could be easily
translated to other chaperones and disaggregases. It would be
interesting to use this strategy for tailoring individual chaperones
toward specificmisfolded proteins involved in neurodegenerative
disease.
COMBINING FUNCTIONALITIES TO
CREATE ACTIVATED CHIMERIC FOLDING
ENZYMES
While most molecular chaperone engineering approaches
improve specific aspects of an existing protein scaffold, another
interesting tactic is to exchange specific chaperone domains to
combine different functionalities and yield enhanced chaperone
chimeras. This approach was used to improve the chaperone
activity of the human prolyl isomerase FKBP12 (hFKBP12)
(Geitner and Schmid, 2012). hFKBP12 is a modest catalyst of
protein folding reactions limited by proline isomerization, as it
only contains a prolyl isomerase active site, and no inherent
chaperone domain (Geitner and Schmid, 2012). As prolyl
isomerases need chaperone function to properly promote protein
folding, Schmid and colleagues inserted three natural chaperone
domains into a loop in hFKBP12 to boost folding activity
of the enzyme (Geitner and Schmid, 2012). Specifically, the
apical domain of GroEL, the chaperone domain of yeast protein
disulfide isomerase (PDI) and the chaperone domain of the
periplasmic E. coli chaperone SurA were used to create chimeras
with hFKBP12 (Geitner and Schmid, 2012). Both protein folding
and peptide isomerization activity were measured to assess the
activity of the chimeras relative to hFKBP12, and although
the chimeric proteins showed a general decrease in peptide
isomerization activity, they displayed a strong improvement in
protein folding ability (Geitner and Schmid, 2012). Overall, the
addition of molecular chaperone domains to folding enzymes to
create a separation of catalytic and client protein binding is an
interesting approach to engineer synthetic folding enzymes with
amplified function. It will be interesting to determine whether
other multidomain chimeric chaperones can be developed for
specific functions.
RISKS OF RE-ENGINEERING MOLECULAR
CHAPERONES AND PROTEIN
DISAGGREGASES
Though enhanced molecular chaperones and disaggregases
could be advantageous to the cell (especially in the context
of excessive deleterious protein misfolding), it is also possible
that inappropriate hyperactivity of these proteins could have
detrimental effects under some circumstances. Indeed, the
potentiated Hsp104 variant, Hsp104A503V, is toxic to yeast under
mild thermal stress conditions of 37◦C (Schirmer et al., 2004;
Jackrel and Shorter, 2014a; Jackrel et al., 2014). We suggest that
under these mild stress conditions, key yeast proteins become
metastable and are subsequently inappropriately targeted and
unfolded by Hsp104A503V (Jackrel and Shorter, 2014a, 2015;
Jackrel et al., 2014). This nonspecific unfolding likely results
in the observed growth defect, which can be suppressed by
overexpression of Hsp90 or Hsp40 (Sis1; Schirmer et al., 2004).
Thus, further engineering is warranted to tailor potentiated
Hsp104 variants to target specific substrates and prevent off-
target effects (Jackrel and Shorter, 2015). Alternatively, transient,
inducible bursts of expression of potentiated Hsp104 variants
at times when they are most needed might also minimize
potentially toxic side effects. It is plausible that these detrimental
effects observed in enhanced Hsp104 variants might also occur
in engineered molecular chaperones with enhanced activity.
Indeed, overexpression of even wild-type molecular chaperones
(e.g., Hsp70) at inappropriate times can be detrimental (Feder
et al., 1992). Thus, the expression of engineered molecular
chaperones may need to be tightly controlled or their activity
may need to be fine-tuned to specific targets to minimize
unwanted off-target effects. Overall, balancing enhanced activity
with minimal unfavorable effects will be a key challenge to
overcome. Overcoming this challenge will likely be invaluable for
combating toxic misfolding events in various diseases.
CONCLUSIONS AND OUTLOOK
Molecular chaperones and protein disaggregases are critical
components of proteostasis networks. Thus, gaining a greater
appreciation for how these complex folding machines function
on both structural and mechanistic levels is of substantial
importance. Ultimately, understanding how to enhance the
activity of molecular chaperones and protein disaggregases may
be useful for combating toxic protein misfolding events in
neurodegenerative disease, as well as large-scale purification of
aggregation-prone proteins for basic and therapeutic purposes.
Overall, insights gleaned from the successful engineering
endeavors outlined above emphasize a number of crucial
themes in developing enhanced chaperone variants. Several
mechanisms for enhancing activity have been uncovered,
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including increasing ATPase activity, altering substrate-binding
regions, grafting substrate-specific binding sites onto chaperones,
and exchanging specific chaperone domains to create improved
chaperone chimeras. Furthermore, introducing flexibility by
making beneficial destabilizing mutations into chaperones, and
targeting regulatory domains as opposed to substrate-binding
domains for modification, have proven valuable strategies for
engineering several chaperones.
Looking to the future, it will be extremely interesting to
synthesize themes from previous chaperone and disaggregase
engineering studies and apply them to re-engineering the
TRiC chaperonin (Lopez et al., 2015) or the metazoan protein
disaggregase system: Hsp110, Hsp70, and Hsp40 (Torrente
and Shorter, 2013; Finka et al., 2015; Nillegoda and Bukau,
2015) to more effectively target detrimental misfolding events
connected to neurodegenerative disease. In this regard, several
lessons learned from our efforts to potentiate Hsp104 activity
are particularly encouraging. At first glance, it might seem
improbable or impossible to improve existing chaperone or
disaggregase activity, which has been hewn over the course
of millions of years of evolution. However, such a view
overestimates the optimality of natural proteins for specific tasks.
Indeed, we now have hundreds of potentiated Hsp104 variants
with improved disaggregase activity against TDP-43, FUS, and
α-synuclein misfolding (Jackrel et al., 2014, 2015). Remarkably,
some of these potentiating changes were extremely subtle. For
example, removal of a methyl group from a side chain or addition
or removal of a single methylene bridge yielded potentiated
forms of Hsp104 (Jackrel et al., 2014, 2015). The relative ease at
which potentiated Hsp104 variants were uncovered leads us to
hypothesize that neuroprotection in diverse devastating diseases
could be broadly realized via remarkably subtle modifications
to existing human chaperones. Moreover, because relatively
small changes in primary sequence can yield large increases in
chaperone or disaggregase activity (Wang et al., 2002; Aponte
et al., 2010; Jackrel et al., 2014; Quan et al., 2014), small molecules
that bind in the appropriate regions could also have potentiating
effects on wild-type chaperones or disaggregases. Thus, it will
be critical to isolate small-molecule enhancers of chaperone
or disaggregase activity, which might be more immediately
translatable. Initial endeavors in this area are yielding promising
results (Wang et al., 2013; Pratt et al., 2015). Developing effective
ways to enhance chaperone and disaggregase activity holds
promise for a wide spectrum of applications.
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